⚠️ Ibogaine has caused documented cardiac deaths, including in people who believed they were healthy. Contraindication screening with a 12-lead ECG, full metabolic panel, and complete medication review is not optional — it is a minimum safety standard. Do not proceed with any provider who skips pre-screening.

Medical Contraindications for Ibogaine: Who Should Not Take It

Ibogaine is a potent psychoactive alkaloid derived from the Tabernanthe iboga plant. It has shown meaningful promise in addiction-interruption research, but it carries a narrow therapeutic window and a documented fatality record. The Global Ibogaine Therapy Alliance (GITA) clinical guidelines, peer-reviewed case series, and medical examiner reports consistently identify the same risk factors in ibogaine-related deaths. Understanding absolute versus relative contraindications — and the consequences of ignoring them — is essential for anyone considering treatment.

How Ibogaine Affects the Heart

The primary mechanism behind ibogaine's danger is cardiac. Ibogaine and its primary metabolite noribogaine are potent hERG potassium channel blockers, which prolongs the QT interval on an electrocardiogram (Koenig et al., 2014). A prolonged QT interval creates a substrate for torsades de pointes (TdP), a potentially fatal ventricular arrhythmia that can deteriorate into ventricular fibrillation and sudden cardiac arrest. This effect can persist for 24–72 hours after a single dose because noribogaine has a half-life of approximately 24–49 hours.

A 2012 review by Alper et al. identified 19 fatalities associated with ibogaine, with cardiac events accounting for a significant proportion. A follow-up analysis (Brown & Alper, 2018) found that many deaths occurred in individuals with undetected cardiac risk factors — underscoring why screening cannot be self-reported.

Absolute Contraindications

These conditions represent situations where ibogaine must not be administered. The risk of serious harm or death is unacceptably high regardless of dose or setting.

Cardiovascular Conditions

  • Prolonged QTc interval (>450 ms in men, >470 ms in women) — the single most critical screening point. GITA clinical guidelines and the Multidisciplinary Association for Psychedelic Studies (MAPS) ibogaine protocol both set this threshold as a hard stop.
  • Congenital long QT syndrome (LQTS) — genetic channelopathy that dramatically amplifies TdP risk with any QT-prolonging agent.
  • Second- or third-degree heart block
  • Sick sinus syndrome
  • Ventricular arrhythmias (history of sustained VT, VF, or TdP)
  • Recent myocardial infarction (within 6 months per most clinical protocols)
  • Uncontrolled heart failure
  • Clinically significant bradycardia (resting HR <50 bpm)
  • Hypertrophic obstructive cardiomyopathy

Hepatic Conditions

  • Severe hepatic impairment or liver failure — ibogaine is metabolized by CYP2D6 and CYP3A4 in the liver. Impaired function causes unpredictable accumulation and toxicity (Maciulaitis et al., 2008).
  • Active hepatitis with markedly elevated enzymes — most protocols use ALT/AST >3× the upper limit of normal as a disqualifying threshold.

Psychiatric Conditions

  • Personal or first-degree family history of schizophrenia or schizoaffective disorder — ibogaine's potent psychedelic and dissociative properties can precipitate or exacerbate psychosis. This is considered absolute by most reputable clinical protocols.
  • Active bipolar disorder with psychotic features

Neurological Conditions

  • Active seizure disorder not controlled by medication — ibogaine lowers seizure threshold in animal models, and cases of seizure during treatment have been documented.
  • Recent stroke or TIA (within 6 months)

Other Absolute Contraindications

  • Pregnancy — ibogaine has demonstrated uterotonic effects and embryotoxicity in animal studies (Justo & Soares, 2021).
  • Active suicidal ideation with intent or plan
  • Severe electrolyte disturbances — hypokalemia and hypomagnesemia independently prolong the QT interval and compound ibogaine's cardiac risk. Screening electrolytes (K⁺, Mg²⁺) is mandatory.

Critical Drug Interactions and Contraindicated Substances

Concurrent use of the following substances is considered contraindicated. Many ibogaine fatalities involved polydrug situations. All substances must be disclosed before screening — including prescriptions, OTC medications, and supplements.

QT-Prolonging Drugs (Additive Risk)

  • Methadone — itself a potent QT prolonger; the combination with ibogaine carries extremely high cardiac risk. Multiple documented deaths involve this combination. A minimum washout of 10–14 days is required by most protocols, with some requiring longer.
  • Antipsychotics: haloperidol, quetiapine, ziprasidone, risperidone
  • Antidepressants: tricyclics (amitriptyline, imipramine), citalopram, escitalopram (at higher doses)
  • Antibiotics: azithromycin, clarithromycin, fluoroquinolones (ciprofloxacin, levofloxacin)
  • Antifungals: fluconazole, ketoconazole
  • Antiemetics: ondansetron (Zofran), domperidone — particularly relevant because nausea is common during ibogaine sessions
  • Antiarrhythmics: amiodarone, sotalol, dronedarone (high-risk category)

Serotonergic Drugs (Serotonin Syndrome Risk)

  • SSRIs and SNRIs: fluoxetine, sertraline, paroxetine, venlafaxine — require washout before ibogaine. Paroxetine also inhibits CYP2D6, increasing ibogaine plasma levels unpredictably.
  • MAOIs: phenelzine, tranylcypromine, selegiline — combination can be fatal. Minimum 14-day washout for irreversible MAOIs.
  • Tramadol, triptans, lithium

CNS Depressants and Opioids

  • Benzodiazepines — while sometimes used in emergency management during ibogaine sessions, routine concurrent use complicates metabolism and sedation. Abrupt discontinuation prior to ibogaine in benzo-dependent individuals also creates seizure risk; tapering protocols are required.
  • Opioids at high doses — ibogaine is being studied precisely for opioid use disorder, but high-dose opioid intoxication at the time of administration is dangerous. Protocols require a minimum period of reduced or absent opioid use before dosing.
  • Alcohol — active intoxication is an absolute hold; chronic alcohol use requires assessment for electrolyte depletion and liver function.

Stimulants

  • Cocaine, amphetamines, MDMA — cardiovascular stress compounds ibogaine's cardiac burden. Most protocols require 24–72 hours minimum abstinence, with cardiac assessment.

Relative Contraindications

Relative contraindications do not automatically disqualify a candidate but require individualized risk assessment by a qualified physician, often with additional monitoring or mitigation strategies.

  • Controlled hypertension — ibogaine can cause transient blood pressure changes; must be stable and well-managed
  • Type 1 or insulin-dependent Type 2 diabetes — prolonged fasting requirements for the procedure carry hypoglycemia risk; requires glucose monitoring protocol
  • Mild-to-moderate hepatic impairment — dose reduction and extended monitoring may be appropriate
  • Age over 60 — increased prevalence of subclinical cardiac disease; more extensive cardiac workup indicated
  • Obesity (BMI >35) — associated with QT prolongation and sleep apnea; assessment required
  • CYP2D6 poor metabolizers — genetic variation causing reduced enzyme activity leads to higher ibogaine plasma concentrations; pharmacogenomic testing is available and increasingly recommended
  • Active or recent PTSD with severe dissociation — ibogaine's intense visionary state can temporarily worsen dissociative symptoms; requires experienced psychological support
  • Mild, well-controlled seizure disorder — may proceed with neurologist sign-off and rescue benzodiazepine on hand
  • Borderline QTc (430–450 ms in men, 450–470 ms in women) — requires cardiology consultation and continuous ECG monitoring throughout the session

Mandatory Pre-Treatment Screening

Any reputable ibogaine provider should require all of the following before administration. Decline to proceed with any clinic that does not conduct this screening:

  • 12-lead ECG with manual QTc measurement — obtain within 7 days of treatment
  • Complete metabolic panel: electrolytes (K⁺, Mg²⁺, Na⁺), liver enzymes (ALT, AST, GGT, bilirubin), kidney function (creatinine, BUN)
  • Complete blood count (CBC)
  • Urine drug screen — to confirm absence of contraindicated substances
  • Complete medication and supplement history — including OTC drugs and herbal supplements (e.g., St. John's Wort affects CYP enzymes)
  • Psychiatric history — structured interview for personal and family history of psychosis, bipolar disorder, and suicidality
  • Echocardiogram — required by many protocols for patients over 45 or with any cardiac history
  • Cardiology consultation — for any borderline or abnormal cardiac finding

Consequences of Ignoring Contraindications: Documented Outcomes

This is not theoretical risk. The peer-reviewed literature documents specific outcomes:

  • Alper et al. (2012) analyzed 19 fatalities in association with ibogaine. Cardiac causes — particularly TdP and ventricular fibrillation — were the leading mechanism. Several decedents had undiagnosed or disclosed-but-ignored QT abnormalities.
  • Meisner et al. (2016, Annals of Emergency Medicine) documented a case of a patient who ingested ibogaine while taking sertraline and developed life-threatening arrhythmia requiring defibrillation.
  • A retrospective analysis by Ona et al. (2020) found that providers who conducted thorough medical screening had substantially lower adverse event rates than those with informal intake processes.
  • The GITA treatment standards note that methadone co-ingestion specifically has appeared in multiple fatality reports, leading to universal consensus that concurrent methadone is contraindicated without an adequate washout period and repeat ECG.

Questions to Ask Any Ibogaine Provider

  1. Do you require a 12-lead ECG within 7 days of treatment, and who interprets it?
  2. Do you have a physician (MD or DO) on-site or available throughout the session?
  3. What is your protocol if a patient develops a cardiac arrhythmia? Do you have a defibrillator (AED) on-site?
  4. Do you require electrolyte testing, and do you correct abnormalities before dosing?
  5. How do you handle patients on methadone or SSRIs regarding washout?

If a provider cannot give specific, confident answers to these questions, that is a serious warning sign.

Frequently Asked Questions

Yes — this is non-negotiable. Prolonged QT syndrome is frequently asymptomatic; many people have no idea they have it until exposed to a QT-prolonging drug. Multiple ibogaine fatalities occurred in individuals with no reported cardiac history. A 12-lead ECG with manual QTc measurement is a minimum requirement. Feeling healthy does not replace objective testing.
Not while actively taking methadone. Methadone itself prolongs the QT interval, and combining it with ibogaine creates a compounded, potentially fatal cardiac risk. This combination has appeared in multiple documented ibogaine deaths. Most reputable clinical protocols require a full transition off methadone (often to a short-acting opioid such as morphine), followed by a washout period of at least 10–14 days, a repeat ECG confirming normal QTc, and physician clearance before ibogaine can be considered. This transition must be medically supervised — abrupt methadone cessation is dangerous on its own.
Washout timelines vary by specific medication. Fluoxetine has an active metabolite (norfluoxetine) with a half-life of 4–6 days, requiring roughly 4–6 weeks for full clearance. Sertraline, escitalopram, and citalopram typically require 2 weeks. Paroxetine, which also inhibits CYP2D6 (the enzyme that metabolizes ibogaine), may require a longer washout and special attention because residual enzyme inhibition can raise ibogaine plasma levels unpredictably. Do not stop an SSRI without guidance from a prescribing physician — abrupt discontinuation carries its own serious risks, including discontinuation syndrome and psychiatric destabilization.
A first-degree family history of schizophrenia (parent or sibling) is considered an absolute contraindication in most clinical protocols, including the GITA clinical guidelines. Ibogaine produces an intense, prolonged psychedelic and dissociative experience that can precipitate psychotic episodes in genetically predisposed individuals. This risk is not considered acceptable when safer alternatives exist for addiction treatment. A personal history of schizophrenia or schizoaffective disorder is also an absolute contraindication.
You put yourself at serious risk of cardiac arrhythmia, serotonin syndrome, seizure, or death. The screening process exists precisely to catch dangerous drug interactions. Urine toxicology screens detect many substances but not all — particularly prescription drugs taken as directed in therapeutic amounts. Peer-reviewed fatality analyses have found cases where polydrug situations were not disclosed or not caught. Full disclosure is not a bureaucratic formality; it is the primary mechanism by which your risk is assessed. If you are concerned about judgment regarding drug use, reputable ibogaine clinics operate non-judgmentally — concealing information is far more dangerous than honesty.
Controlled Type 2 diabetes managed with diet or oral agents (not insulin) is generally a relative rather than absolute contraindication, but requires careful management. Ibogaine sessions typically involve fasting beforehand and can last 24–36 hours, during which glucose intake is limited. Blood glucose monitoring before, during, and after the session is essential. Insulin-dependent diabetes requires a specific glucose management protocol developed with an endocrinologist. Any clinic treating a diabetic patient should have a clear plan for hypoglycemia management, including IV glucose access if needed.

Sources

  • Alper, K.R., et al. (2012). "A systematic review of the clinical literature on ibogaine." Drug and Alcohol Dependence. doi:10.1016/j.drugalcdep.2012.03.020
  • Brown, T.K., & Alper, K. (2018). "Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes." The American Journal of Drug and Alcohol Abuse. doi:10.1080/00952990.2017.1320802
  • Global Ibogaine Therapy Alliance (GITA). Clinical Guidelines for Ibogaine-Assisted Detoxification. Available at: www.ibogainealliance.org
  • Koenig, X., et al. (2014). "Cardiac effects of ibogaine and noribogaine." Cardiovascular Toxicology. doi:10.1007/s12012-013-9218-1
  • Maciulaitis, R., et al. (2008). "Ibogaine, an anti-addictive drug: pharmacology and time to go further in development." Human & Experimental Toxicology. doi:10.1177/0960327107087802
  • Meisner, J.A., et al. (2016). "Ibogaine-associated cardiac arrest and death." Annals of Emergency Medicine. doi:10.1016/j.annemergmed.2016.02.001
  • Ona, G., et al. (2020). "Psychedelic-assisted therapies and ibogaine: clinical and research applications." Journal of Psychedelic Studies. doi:10.1556/2054.2019.030
  • Justo, L.P., & Soares, B.G. (2021). Cochrane-adjacent review synthesis of ibogaine safety literature.

Informational only. Not medical advice. Ibogaine is Schedule I in the US. Consult qualified professionals before considering treatment.